Few topics in men’s health generate more debate than when, how, and even whether to screen for prostate cancer. Prostate cancer screening centers on the PSA blood test, sometimes paired with a digital rectal exam, and the goal is to find lethal cancers early without subjecting men to harms from treating cancers that would never have caused trouble. Modern guidelines have shifted toward shared decision-making rather than blanket recommendations.
What Screening Aims to Do
Screening is testing healthy men without symptoms to find cancer earlier than it would otherwise present. The hoped-for benefit is reduced prostate cancer mortality. The hoped-against harms include false positives leading to biopsies, overdiagnosis of indolent cancers, and overtreatment that causes incontinence and erectile dysfunction in men whose cancers never would have shortened their lives.
Two large trials shaped the modern debate. The European Randomized Study of Screening for Prostate Cancer (ERSPC) showed a 21 percent relative reduction in prostate cancer mortality with PSA screening at 16 years of follow-up. The US-based PLCO trial found no mortality benefit, though contamination (men in the control arm getting PSA tests) limited interpretation. Together they suggest a real but modest mortality benefit accompanied by substantial overdiagnosis.
Current Guidelines
The American Urological Association’s 2023 early detection guideline recommends shared decision-making, with a baseline PSA between ages 45 and 50 for men of average risk and earlier (40 to 45) for higher-risk men, including African Americans and those with a strong family history of prostate, breast, ovarian, or pancreatic cancer or known BRCA mutations. Repeat testing intervals depend on the baseline result.
The US Preventive Services Task Force recommends individualized decision-making for men 55 to 69 (Grade C) and recommends against PSA screening for men 70 and older (Grade D). The American Cancer Society endorses informed shared decision-making starting at 50 for average risk and earlier for higher-risk men.
All three groups now agree that the conversation matters more than a default yes-or-no answer. The medical conditions library covers related screening topics in men’s health.
How PSA Testing Works
PSA, prostate-specific antigen, is a protein produced almost entirely by prostate cells. Higher levels are associated with prostate cancer but also with BPH, prostatitis, recent ejaculation, vigorous bicycling, and digital rectal exam. The traditional cutoff of 4 ng/mL identifies many cancers but misses some and prompts unnecessary biopsies in others.
Refinements include age-adjusted ranges (about under 2.5 ng/mL for men under 50, under 3.5 for men in their 50s, under 4.5 for men in their 60s, under 6.5 for men in their 70s in some frameworks), PSA density (PSA divided by prostate volume), PSA velocity (rate of change over time), and free PSA percentage. The PSA test guide goes deeper on interpretation.
Digital Rectal Exam
The DRE has lost prominence as a screening tool. Most prostate cancers detected by DRE alone are advanced, and DRE has limited sensitivity for early disease. The 2023 AUA guideline notes that DRE is no longer required as a routine screening tool when PSA is being measured, though it retains value in symptomatic men and in evaluating an abnormal PSA.
What Happens After an Abnormal PSA
An elevated PSA does not equal cancer. The first step is usually repeat testing to confirm, sometimes after waiting a few weeks if recent activities (cycling, ejaculation, prostatitis) may have skewed the result. Secondary tests refine risk before biopsy. Free-to-total PSA percentage, the 4Kscore, the Prostate Health Index (PHI), and urine-based markers like SelectMDx and ExoDx help estimate the probability of clinically significant cancer.
Multiparametric MRI of the prostate has become standard before biopsy in many practices. Lesions are scored using PI-RADS 1 to 5, and only PI-RADS 3 to 5 lesions typically prompt targeted biopsy. The MRI-first pathway reduces unnecessary biopsies and improves detection of clinically significant cancers per the PRECISION trial.
Benefits and Harms
The mortality benefit of screening is real but modest. Estimates from ERSPC suggest screening one man for 13 to 16 years prevents about 1.3 prostate cancer deaths per 1,000 men screened. Approximately 17 to 27 men need to be diagnosed for each death prevented because of overdiagnosis. False positive PSAs lead to biopsies, which carry small risks of bleeding, infection, and pain.
Treatment harms hinge on what is done after diagnosis. Modern active surveillance for low-risk disease has substantially reduced overtreatment. The newer pathway, screen-confirm-MRI-biopsy-stratify-and-watch-when-appropriate, looks very different from the older pattern of biopsy-treat-immediately that dominated the 1990s and 2000s.
When to See a Doctor
A primary care visit between ages 45 and 50 is a reasonable opportunity to discuss screening for average-risk men. Men with a father or brother diagnosed with prostate cancer (especially before age 65), African American men, and known BRCA carriers should consider starting the conversation by 40 to 45.
When to seek emergency care: Call 911 or go to the nearest emergency room if you experience high fever above 101 degrees Fahrenheit, chills, or signs of sepsis after a prostate biopsy, severe rectal or pelvic pain following biopsy, or inability to urinate.
Frequently Asked Questions
At what age should I stop PSA screening?
Most guidelines suggest stopping when life expectancy is less than 10 to 15 years, which is typically around age 70 to 75 for healthy men. Men in poor health may stop earlier; very healthy men in their 70s with prior abnormal PSAs may continue selectively.
Can I have an elevated PSA without cancer?
Yes. BPH, prostatitis, recent ejaculation within 48 hours, vigorous cycling, and recent digital rectal exam can all elevate PSA. About 70 to 75 percent of men with PSA between 4 and 10 ng/mL who undergo biopsy do not have cancer.
Does ejaculation affect PSA?
Ejaculation can transiently raise PSA. Many clinicians ask men to abstain for 48 hours before the test to minimize this effect.
Is the digital rectal exam still done?
It is performed less routinely than in past decades. The AUA’s 2023 guideline considers PSA the primary screening tool, with DRE used selectively rather than universally.
The Bottom Line
Prostate cancer screening is no longer a reflexive yes or no. The current consensus is that men deserve a real conversation about benefits and harms, ideally starting in their mid-40s for higher-risk men and around 50 for average-risk men. A baseline PSA paired with shared decision-making, MRI-first evaluation of abnormal results, and active surveillance for low-risk findings now represents best practice. The goal is finding the cancers that matter while leaving the indolent ones alone.